Deignan Charles A. 4
4 · Clearside Biomedical, Inc. · Filed Jan 20, 2022
Insider Transaction Report
Form 4
Deignan Charles A.
Chief Financial Officer
Transactions
- Award
Common Stock
2022-01-18+43,750→ 360,199 total - Sale
Common Stock
2022-01-19$2.09/sh−8,833$18,461→ 351,366 total - Award
Stock Option (Right to Buy)
2022-01-18+131,250→ 131,250 totalExercise: $2.19Exp: 2032-01-18→ Common Stock (131,250 underlying)
Footnotes (4)
- [F1]These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
- [F2]The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.0902 to $2.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.